Company Insights

OKYO supplier relationships

Explore interactive graphBrowse insights index
OKYO supplier relationship map

OKYO Pharma: a capital markets-driven supplier profile for investors

OKYO Pharma Ltd (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company currently monetizes through equity markets and is funding clinical development via at‑the‑market (ATM) facilities and public offerings rather than product revenue — the balance sheet and banking relationships therefore define near-term value creation and dilution risk. For a concise supplier and partner map tied to OKYO’s FY2026 capital activity, see more at https://nullexposure.com/.

How OKYO funds development and why partnerships matter

OKYO is a non‑revenue, R&D‑intensive issuer with negative EBITDA and no product sales; its operating model is structured around securing incremental capital for trials. That creates a financing-first posture: banks and placement agents (ATM sales agents, book‑runners) are strategically critical and have direct commercial leverage through placement commissions and market access. OKYO’s FY2026 public offering activity and ATM transition are the definitive supplier interactions for the current fiscal runway. Learn more about supplier exposures at https://nullexposure.com/.

Media and communications are small but deliberate commercial levers

OKYO also pays for selective investor‑relations and media visibility. Small, recurring paid media arrangements increase market awareness for clinical milestones and financing windows, which supports execution of equity raises and ATM placements. Paid coverage is not a substitute for capital but does materially affect placement cadence and retail/institutional interest.

Every recorded relationship — one by one

Below is a concise, item‑by‑item mapping of every relationship captured in our FY2026 results feed, with a short plain‑English description and source reference for each entry.

  1. Piper Sandler & Co. — A Yahoo Finance item reported that Piper Sandler is serving as sole manager for an offering tied to the company’s financing activity. (Yahoo Finance, March 10, 2026)
    Source: https://finance.yahoo.com/news/okyo-pharma-announces-pricing-20-032000675.html

  2. Leerink Partners LLC — Sahm Capital reported that OKYO transitioned its ATM equity offering facility to Leerink Partners as sales agent, replacing the prior ATM arrangement. (Sahm Capital, Feb 11, 2026)
    Source: https://www.sahmcapital.com/news/content/okyo-pharma-announces-transition-of-at-the-market-equity-offering-facility-to-leerink-partners-2026-02-11

  3. B. Riley Securities Inc. — A GlobeNewswire release noted that OKYO previously had an ATM facility with B. Riley that has been replaced in the transition to a new sales agent. (GlobeNewswire, Feb 11, 2026)
    Source: https://www.globenewswire.com/news-release/2026/02/11/3236441/0/en/OKYO-Pharma-Announces-Transition-of-At-The-Market-Equity-Offering-Facility-to-Leerink-Partners.html

  4. Leerink Partners LLC (GlobeNewswire) — GlobeNewswire confirmed that Leerink will act as exclusive sales agent and receive a commission equal to 3.0% of gross proceeds from any shares sold under the ATM. (GlobeNewswire, Feb 11, 2026)
    Source: https://www.globenewswire.com/news-release/2026/02/11/3236441/0/en/OKYO-Pharma-Announces-Transition-of-At-The-Market-Equity-Offering-Facility-to-Leerink-Partners.html

  5. Piper Sandler & Co. (GlobeNewswire) — A separate GlobeNewswire filing announced that OKYO priced a $20.0 million public offering of ordinary shares with Piper Sandler acting as sole manager. (GlobeNewswire, Feb 13, 2026)
    Source: https://www.globenewswire.com/news-release/2026/02/13/3237817/0/en/OKYO-Pharma-Announces-Pricing-of-20-Million-Public-Offering-of-Ordinary-Shares.html

  6. Proactive financial news (Proactive Investors CA) — An article discloses that Proactive receives annual cash compensation (typically up to $25,000) from OKYO for publishing and promotion services. (Proactive Investors, 2026)
    Source: https://www.proactiveinvestors.ca/companies/news/1085118/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-new-ceo.html?region=ca

  7. Proactive financial news (Proactive Investors) — A second Proactive item repeats the paid‑client disclosure for OKYO press coverage and promotion, confirming a recurring paid publishing arrangement. (Proactive Investors, 2026)
    Source: https://www.proactiveinvestors.com/companies/news/1085117/okyo-pharma-names-ophthalmology-veteran-robert-dempsey-as-ceo-1085117.html

  8. Proactive (public offering coverage) — Proactive published a piece on the $20M offering that includes the disclosure “published on behalf of OKYO Pharma Ltd, a paid client of Proactive.” (Proactive, 2026)
    Source: https://www.proactiveinvestors.com/companies/news/1087349/okyo-pharma-prices-20m-offering-to-fund-late-stage-eye-drug-trial-1087349.html

  9. B. Riley Securities Inc. (Sahm Capital reference) — Sahm Capital’s syndicated coverage references B. Riley as OKYO’s prior ATM counterparty, reinforcing the replacement of that prior facility. (Sahm Capital, Feb 11, 2026)
    Source: https://www.sahmcapital.com/news/content/okyo-pharma-announces-transition-of-at-the-market-equity-offering-facility-to-leerink-partners-2026-02-11

  10. Proactive (analyst and FDA coverage) — Proactive published an article noting analyst optimism after the FDA endorsed OKYO’s Phase 2b/3 trial design; the item includes “paid client” disclosure. (Proactive, 2026)
    Source: https://www.proactiveinvestors.co.uk/companies/news/1087499/okyo-pharma-has-analysts-bullish-as-fda-endorses-phase-2b-3-trial-in-neuropathic-corneal-pain-1087499.html

  11. Piper Sandler & Co. (SG Finance Yahoo) — A Singapore Yahoo Finance repost again identified Piper Sandler as sole manager for the offering, reflecting broad syndication of the placement notice. (Yahoo Finance Singapore, March 10, 2026)
    Source: https://sg.finance.yahoo.com/news/okyo-pharma-announces-pricing-20-032000675.html

  12. Proactive Group Holdings Inc — Proactive’s UK feed reiterates the paid‑promotion disclosure while reporting OKYO’s clearance of a key FDA meeting for the urcosimod Phase 2b/3 trial. (Proactive Group Holdings, 2026)
    Source: https://www.proactiveinvestors.co.uk/companies/news/1086421/okyo-pharma-clears-key-fda-meeting-for-urcosimod-phase-2b3-trial.html

  13. Leerink Partners (Finviz) — Finviz aggregated the announcement that OKYO appointed Leerink Partners as sales agent for the ATM facility, echoing the market distribution of the transaction. (Finviz, March 2026)
    Source: https://finviz.com/news/305455/okyo-pharma-strengthens-world-class-leadership-team-with-appointment-of-flavio-mantelli-md-phd-as-chief-medical-officer

  14. Piper Sandler & Co. (GlobeNewswire Feb 12) — GlobeNewswire also reported Piper Sandler acting as sole book‑running manager for the related public offering documentation. (GlobeNewswire, Feb 12, 2026)
    Source: https://www.globenewswire.com/news-release/2026/02/12/3237645/0/en/OKYO-Pharma-Announces-Public-Offering-of-Ordinary-Shares.html

  15. Proactive (press coverage disclosure) — Another Proactive post on clinical updates reiterates that the record is published on behalf of OKYO and that Proactive is a paid client engagement. (Proactive, 2026)
    Source: https://www.proactiveinvestors.com/companies/news/1086421/okyo-pharma-clears-key-fda-meeting-for-urcosimod-phase-2b3-trial.html

  16. Proactive Group Holdings Inc (duplicate feed) — Proactive’s various regional feeds consistently include the paid-client disclosures across reporting on OKYO’s clinical and financing milestones. (Proactive Group Holdings, 2026)
    Source: https://www.proactiveinvestors.co.uk/companies/news/1086421/okyo-pharma-clears-key-fda-meeting-for-urcosimod-phase-2b3-trial.html

  17. (Syndicated aggregate entries) — Multiple outlets republished the same GlobeNewswire and PR materials—this syndication amplifies the financing and ATM transition message across retail and wholesale channels. (GlobeNewswire / Yahoo / Finviz, Feb–Mar 2026)
    Source examples: https://www.globenewswire.com/, https://finance.yahoo.com/, https://finviz.com/

  18. (Media compensation disclosures repeated) — Across several items the Proactive family of sites repeatedly discloses an annual promotional fee (up to $25,000) paid by OKYO, reflecting an ongoing paid media relationship. (Proactive network, 2026)
    Source examples: https://www.proactiveinvestors.com/, https://www.proactiveinvestors.co.uk/

What these relationships imply about OKYO’s operating model and risk posture

  • Contracting posture: OKYO relies on short‑term capital contracts (ATM sales agent agreements and book‑running manager mandates) rather than long-term revenue contracts. The 3.0% ATM sales commission is a fixed transactional cost aligned with financing volume.
  • Concentration: Equity markets and a small set of healthcare banks (Piper Sandler, Leerink, previously B. Riley) are high‑concentration suppliers — their willingness to place shares controls liquidity and dilution timing.
  • Criticality: These bank relationships are mission‑critical for OKYO’s ability to run a Phase 2b/3 trial; without access to the equity markets the company’s cash runway and trial execution are at direct risk.
  • Maturity and cash profile: OKYO is clinical‑stage with no reported revenue (RevenueTTM = 0) and negative operating metrics; capital supply, not commercial traction, currently drives valuation.
  • Communications posture: Small paid media arrangements (annual fees typically up to $25k) indicate deliberate investor‑relations spend targeted at amplifying financing and regulatory milestones.

Bottom line and recommended next steps

OKYO’s supplier map is dominated by capital markets partners and a small set of paid media vendors — these suppliers determine both funding capacity and market perception. For investors, the primary monitoring checklist is: execution of the ATM/public offering, commission and placement terms, and any changes in sales‑agent or book‑runner status. For counterparties or operators evaluating engagement with OKYO, treat financing relationships as de facto operational suppliers with high criticality.

For more supplier profiles, capital‑markets exposure maps, and ongoing tracking of OKYO’s counterparty network, visit https://nullexposure.com/. If you want an investor‑grade supplier risk brief tailored to OKYO’s FY2026 financing events, review our site and request a bespoke report at https://nullexposure.com/.